Skip to content

Renal ablation articles

Published December 30, 2019

  1. Jain, R, Dallas, A, Xu, H, Shwaiki, O, Salloum, E, Tong, WL et al.. Ectopic adrenal cortical adenoma arising within the kidney in the setting of adrenal-renal fusion: Two cases mimicking renal cell carcinoma and the role of biopsy and ablation. Radiol Case Rep. 2026;21 (11):5306-5313. doi: 10.1016/j.radcr.2026.07.062. PubMed PMID:42622011 PubMed Central PMC13488045.
  2. Kim, DH, Keshavarz, P, Tibbe, TD, Suh, RD, Abtin, F, Genshaft, SJ et al.. Long-Term Survival After Percutaneous Image-Guided Thermal Ablation of Oligometastatic Renal Cell Carcinoma. J Vasc Interv Radiol. 2026; :109040. doi: 10.1016/j.jvir.2026.109040. PubMed PMID:42617973 .
  3. Sugawara, S, Kurokawa, R, Ide, S, Yanagawa, M, Iima, M, Saida, T et al.. Percutaneous thermal ablation for renal cell carcinoma: a comprehensive review of current evidence and future directions. Radiol Med. 2026; :. doi: 10.1007/s11547-026-02240-x. PubMed PMID:42613495 .
  4. Kim, DH, Chen, L, Shuch, B, Pantuck, A, Lu, DSK, Raman, SS et al.. Long-Term Survival after Percutaneous Image-Guided Microwave Ablation of Pathologically Proven Renal Cell Carcinoma. J Vasc Interv Radiol. 2026; :109035. doi: 10.1016/j.jvir.2026.109035. PubMed PMID:42607882 .
  5. Yang, J, Wang, X, Li, Z, Zhang, Z, Zhang, M, Sun, Z et al.. Radiofrequency Ablation for Recurrent Renal Tumors After Partial Nephrectomy: A Retrospective Cohort Study of Technical Considerations and Oncologic Outcomes. J Endourol. 2026; :8927790261473185. doi: 10.1177/08927790261473185. PubMed PMID:42572240 .
  6. Miyajima, K, Ishihara, K, Yamada, T, Yabuzaki, R, Oda, Y, Nanjo, K et al.. Hemolysis and renal tubular injury after pulsed field ablation: A comparison between two commercially available platforms. Heart Rhythm. 2026; :. doi: 10.1016/j.hrthm.2026.07.043. PubMed PMID:42551685 .
  7. Harbich, PF, Auer, L, Tinhofer, F, Burger, AL, Eberl, T, Weltler, P et al.. Early Hemolysis, Myolysis and Renal Stress Following Pentaspline Pulsed Field Versus Radiofrequency Ablation of Atrial Fibrillation. Eur J Clin Invest. 2026;56 (8):e70248. doi: 10.1111/eci.70248. PubMed PMID:42568340 PubMed Central PMC13451952.
  8. Rocchetti, M, Schaack, D, Marrese, A, Urbani, A, Kheir, J, Najafi, S et al.. Haemolysis and renal effects across pulsed field ablation systems in atrial fibrillation. Europace. 2026;28 (8):. doi: 10.1093/europace/euag190. PubMed PMID:42530033 PubMed Central PMC13439313.
  9. Covello, C, Isufi, I, Pinho, JP, Crafa, F, Larghi, A. Endoscopic ultrasound-guided radiofrequency ablation of a mediastinal lymph node metastasis from clear cell renal cell carcinoma. Endoscopy. 2026;58 (S 04):E853-E854. doi: 10.1055/a-2873-7665. PubMed PMID:42526512 PubMed Central PMC13441506.
  10. Lukies, M, Ormiston, W, Brown, N, Chan, P, Al-Hindawi, A, Popuri, R et al.. Interventional Radiology Society of Australasia Quality Care Guidelines for Renal Tumour Ablation in Australia and New Zealand. J Med Imaging Radiat Oncol. 2026; :. doi: 10.1111/1754-9485.70148. PubMed PMID:42521644 .
  11. Fujimori, M, Yamanaka, T, Matsushita, N, Kishi, S, Nagata, C, Kato, H et al.. Long-term Clinical Outcomes of Radiofrequency Ablation for Pathologically Diagnosed T1a Renal Cell Carcinoma: A 10-Year Single-center Experience. Interv Radiol (Higashimatsuyama). 2026;11 :e20250113. doi: 10.22575/interventionalradiology.2025-0113. PubMed PMID:42445307 PubMed Central PMC13364337.
  12. Ferrillo, G, Baldassarre, E, Sirugo, T, Romano, S, Lanza, E, Poretti, D et al.. First report of safety and outcomes of radiofrequency ablation of renal tumors using a new automated energy delivery-controlled system. Minerva Urol Nephrol. 2026;78 (3):363-372. doi: 10.23736/S2724-6051.26.06732-7. PubMed PMID:42438982 .
  13. Iacovelli, R, Ciccarese, C, Arduini, D, Tagliaferri, L, Minervini, A, Simone, G et al.. The ITALIC-RCC: A Randomized Trial on Clinical and Humoral Impact of Primary Tumor Ablation by Surgery or Radiotherapy in Metastatic Renal Cell Carcinoma Treated with Checkpoint Inhibitors. Eur Urol Open Sci. 2026;90 :77-83. doi: 10.1016/j.euros.2026.06.004. PubMed PMID:42433301 PubMed Central PMC13351335.
  14. Borgbjerg, J, Nielsen, TK, Graumann, O. Clarifying Recurrence, Bleeding Risk, and Procedural Burden in Central Renal Tumor Ablation. J Vasc Interv Radiol. 2026;37 (10):108947. doi: 10.1016/j.jvir.2026.108947. PubMed PMID:42409308 .
  15. Madoff, DC, Farhan, A. Reply to "Clarifying Recurrence, Bleeding Risk, and Procedural Burden in Central Renal Tumor Ablation". J Vasc Interv Radiol. 2026;37 (10):108948. doi: 10.1016/j.jvir.2026.108948. PubMed PMID:42401368 .
  16. Gan, J, Gan, J, Jiang, Y, Li, J, Yang, X, Deng, Z et al.. Percutaneous thermal ablation of the parathyroid glands is associated with short-term echocardiographic improvements in left ventricular structure and function in patients with end-stage renal disease and secondary hyperparathyroidism. Int J Hyperthermia. 2026;43 (1):2680506. doi: 10.1080/02656736.2026.2680506. PubMed PMID:42393012 .
  17. Gan, JX, Li, MF, Deng, HH, Liu, QT, Chen, ZX, Liang, CL et al.. Ablation of the renal tubular gluconeogenic enzyme PCK1 drives AKI-to-CKD transition by negatively regulating the TGF-β/Smad3 signaling pathway. Cell Mol Life Sci. 2026; :. doi: 10.1007/s00018-026-06310-1. PubMed PMID:42380498 .
  18. Schubert, O, Sighinolfi, MC, Gavi, F, Panio, E, Assumma, S, Silvestri, A et al.. Correction: Schubert et al. Minimally Invasive Ablation Strategies for Renal Cell Carcinoma Patients Ineligible for Surgery. Life 2026, 16, 73. Life (Basel). 2026;16 (6):. doi: 10.3390/life16060919. PubMed PMID:42355565 PubMed Central PMC13302591.
  19. Lucignani, G, Bigot, P, Roupret, M, Parier, B, Branger, N, Champy, C et al.. Partial Nephrectomy Versus Thermal Ablation for Cystic Renal Tumors: A Registry-Based, Propensity Score Matched Analysis (UroCCR n°177). Cardiovasc Intervent Radiol. 2026; :. doi: 10.1007/s00270-026-04482-8. PubMed PMID:42337129 .
  20. Yoo, YJ, Jiyoon, L, Park, KJ, Song, C, Kim, YJ, Kim, YS et al.. Oncologic outcomes and renal function preservation after stereotactic ablative body radiotherapy versus radiofrequency ablation in stage I renal cell carcinoma. Clin Transl Radiat Oncol. 2026;60 :101193. doi: 10.1016/j.ctro.2026.101193. PubMed PMID:42305853 PubMed Central PMC13266214.
Search PubMed

Published in Uncategorized